Twelve consecutively diagnosed children with brain tumors, ages 7 to 27 months, were treated by a combined-modality approach featuring aggressive surgical resection followed by chemotherapy and delayed irradiation. Patients received multiple clinical neurologic examinations and psychological evaluations, as well as diagnostic imaging studies, to monitor the efficacy of chemotherapy and toxic effects of therapy. Six of the eight children with residual tumor evident postoperatively on computed tomography scans had objective responses to chemotherapy. The efficacy of chemotherapy was further demonstrated by the lack of disease progression for 7 months or longer in eight children, seven of whom remain free of tumor 19 to 57 months (median, 28 months) from the date of diagnosis. The neurologic status of ten patients improved during treatment. Developmental progress was normal in two, low average in three, and frankly deficient in four of ten children formally evaluated. These results indicate that postoperative chemotherapy, added to a regimen of surgical resection and delayed irradiation, prolong survival with only minimal short term neurotoxicity in the majority of very young children with malignant brain tumors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/1097-0142(19880201)61:3<428::aid-cncr2820610304>3.0.co;2-a | DOI Listing |
JAMA Netw Open
January 2025
Department of Neurosurgery and Brain Metastasis Center, Memorial Sloan Kettering Cancer Center, New York, New York.
Importance: Approximately one-third of patients with ERBB2 (formerly HER2 or HER2/neu)-positive (ERBB2+) metastatic breast cancer (MBC) develop brain metastasis. It is unclear whether patients with disease limited to the central nervous system (CNS) have different outcomes and causes of death compared with those with concomitant extracranial metastasis.
Objective: To assess overall survival (OS) and CNS-related mortality among patients with ERBB2+ breast cancer and a diagnosis of CNS disease by disease distribution (CNS only vs CNS plus extracranial metastasis).
Neurosurg Rev
January 2025
Université Technologique Bel Campus, University in Kinshasa, SKinshasa, Democratic Republic of Congo.
J Neurooncol
January 2025
Department of Neurosurgery, MacKay Memorial Hospital, No. 92, Sec. 2, Zhongshan N. Rd, Taipei, 10449, Taiwan.
Purpose: Advances in multidisciplinary treatment of childhood brain tumors have significantly prolonged survival and reduced treatment-related complications. This makes the accessibility of digital neurocognitive assessment an important issue in the post-pandemic era.
Methods: Twenty pediatric brain tumor patients were recruited between August 2023 and August 2024, and a total of eight standardized Cambridge Neuropsychological Test Automated Battery (CANTAB) tests targeting executive function, memory, and attention were applied on a digital system.
Acta Neurochir (Wien)
January 2025
Department of Neurosurgery, LMU University Hospital, Ludwig-Maximilians-University Munich, Marchioninistrasse 15, 81377, Munich, Germany.
Purpose: Treatment strategies for space-occupying/symptomatic pineal cysts (PC) are still up for debate. In this study we present PC management, outcome data and risk factors for recurrence after surgery, focusing on microscopic/endoscopic procedures vs. stereotactic catheter implantation as alternative treatment concept to permanently drain PC into ventricles/cisterns.
View Article and Find Full Text PDFJ Cancer Res Clin Oncol
January 2025
Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Purpose: This study aims to propose a classification system to more accurately understand the features and nature of different CPs, to investigate the correlation between different topographies of CPs and their surgical outcomes.
Methods: A retrospective analysis was conducted on 91 surgically resected CPs. They were categorized into six types based on their location and origin.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!